• 1H revenue up 17% to $44.1 million
• Gross margin improved to 35.6% from 27.1% in 1H FY25
• EBITDA up 60% to $6.9 million, NPAT up 75% to $4.2 million

Clover Corporation Limited (ASX:CLV) has reported a strong financial and operational performance for the six months ended 31 January 2026. Revenue increased by 17% to $44.1 million, driven by continued recovery across Europe and ANZ markets with existing customer growth and new customer onboarding. Gross margin improved significantly, rising 850 basis points to 35.6% from 27.1% in 1H FY25, due to favorable customer and product mix, as well as improved manufacturing performance. EBITDA increased by 60% to $6.9 million, and NPAT was up 75% to $4.2 million. The company's strategic investments in innovation, including new products such as CholineXcel and DHA/ARA diversification, are contributing to the improved performance. Clover's 43.9% owned Melody Dairies facility in New Zealand is also delivering continued improvements in plant utilization and efficiency. The company has provided revenue guidance of $92-96 million for the full FY26 year, subject to geopolitical stability and supply chain conditions remaining favorable.

Revenue guidance for FY26 is $92 - 96 million.

The Board anticipates that the positive momentum from the first half of FY26 will carry forward, resulting in a stronger second half, based on current demand forecasts. This outlook assumes that geopolitical tensions will not worsen and supply chains will remain stable, ensuring both inbound material supplies and outbound shipments are not disrupted throughout the rest of the financial year.